Botox Is a Brand, Not a Category: The Six Neurotoxins and the Unit Math Nobody Explains

Almost nobody books a neuromodulator appointment. They book Botox. The word has done what Kleenex and Xerox did before it, absorbing an entire product category into one trademark, and the consequence is that most patients walk into a treatment room without knowing that the syringe could contain any of six different approved products, made by five different companies, measured in units that do not mean the same thing.

That last part is not a technicality. It is the reason a patient can pay less per unit and spend more per visit, get a weaker result at an identical number, or conclude that a product "stopped working" when what actually changed was the label on the vial. The neurotoxin market is one of the few places in aesthetics where the consumer-facing math is genuinely misleading, and it is misleading in a way that survives because almost no one explains it.

There are six approved products, not one

The short answer: the United States has six botulinum toxin type A products approved for cosmetic treatment of frown lines, and Botox Cosmetic is simply the oldest of them.

The list, in order of approval: onabotulinumtoxinA (Botox Cosmetic, approved for glabellar lines in 2002), abobotulinumtoxinA (Dysport, 2009), incobotulinumtoxinA (Xeomin, 2011), prabotulinumtoxinA (Jeuveau, 2019), daxibotulinumtoxinA (Daxxify, 2022), and letibotulinumtoxinA (Letybo, 2024). A type B product, rimabotulinumtoxinB, exists but lives almost entirely in therapeutic neurology and is a poor routine substitute for cosmetic work.

All of them do the same fundamental thing. They block the release of acetylcholine at the junction between nerve and muscle, the muscle stops contracting fully, and the skin folding over that muscle stops creasing. All of them carry the same class boxed warning about the possible spread of toxin effect away from the injection site. All of them wear off, because the nerve terminal regenerates its signaling machinery. The differences sit in formulation, in dosing convention, and in marketing, and they are smaller than the advertising implies and larger than "they are all the same" implies.

A unit is not a universal measure

The short answer: potency units are defined separately by each manufacturer, they are specific to that product, and the FDA states plainly that units of one botulinum toxin product cannot be converted into units of another.

This is the single most important thing a patient can know about this category. A unit is not a milligram. It is a potency measurement derived from each manufacturer's own biological assay, and the assays are not the same. In practice, the widely used clinical convention is that Dysport requires roughly two and a half to three of its units to approximate one unit of Botox, with the exact ratio still argued over in the literature and varying by indication and injector. Xeomin and Jeuveau are generally used at close to one-to-one with Botox. Daxxify uses its own scale again.

Now watch what that does to a price. A clinic advertising Dysport at four dollars per unit and a clinic advertising Botox at twelve dollars per unit look wildly different on a billboard. Treat the same frown lines at both and the totals can land within a few dollars of each other, because the Dysport visit uses roughly three times as many units. A patient shopping on per-unit price alone is not comparing prices. They are comparing measurement systems.

The same arithmetic explains a common and avoidable disappointment. A patient treated for years at one practice moves, goes somewhere new, asks for "the same amount I always get," and receives that number in a different product. If the conversion is not done deliberately, the dose is wrong, and the result is weak. That is a units error, not a biological one, and it is one of the ordinary explanations that should be ruled out before anyone starts talking about true resistance to the toxin.

"

Ask what you paid per unit and you have asked a question that cannot be answered across brands. Ask what you paid for the treated area, and what product and dose produced it, and you have asked something a practice can actually be held to.

"

What actually differs between them

The short answer: the meaningful differences are in the accessory proteins, the stabilizer, and the duration claims, and only one of those has a strong evidence base behind its marketing.

Conventional type A products arrive as the core 150 kilodalton neurotoxin bound up with accessory complexing proteins from the bacterial culture. Xeomin is formulated without those accessory proteins, which is why it can be stored at room temperature before reconstitution and why its manufacturer has argued for a lower immunogenic load. Independent evidence that this produces a clinically meaningful advantage for the average patient is thinner than the pitch, though it remains a reasonable option to try in a suspected non-responder.

Daxxify is the more interesting formulation change. Instead of human serum albumin, it uses a proprietary peptide as its stabilizing excipient, and the manufacturer's phase three program reported median durations substantially longer than the three to four months that has been the category norm for two decades. Treat those numbers with the caution any manufacturer-run duration endpoint deserves. Duration in this field is measured against investigator and patient assessment scales that are not identical across trials, head-to-head comparisons against the incumbent are limited, and the practical experience of injectors has been more varied than the launch materials suggested. It is a real formulation difference. It is not yet a settled clinical one.

Onset is the smallest real difference and the one patients notice most. Dysport is commonly described as showing effect a little sooner, sometimes within two to three days, with the rest arriving by two weeks like everything else. Claims about one product spreading further through tissue than another are older, contested, and heavily dependent on dilution and injection technique, which means they say as much about the injector as the vial.

The machinery that decides which brand you get

The short answer: manufacturer loyalty programs, volume purchasing agreements, and per-unit pricing psychology influence brand selection at least as much as clinical reasoning does.

Every major manufacturer runs a patient rewards program, and those programs are tied to the manufacturer's full portfolio, which typically includes its fillers and its skincare line. A practice that has aligned with one company's ecosystem has commercial reasons to keep patients inside it. None of that is scandalous, and none of it means the product chosen is wrong. It does mean that "we prefer this one" is often a statement about a purchasing relationship rather than a conclusion drawn from your face.

The per-unit pricing convention deserves its own scrutiny for the same reason. It is the format that makes a lower-potency unit look like a discount, and it is the format that makes it easy to quietly reduce a dose over time while holding the price steady. Practices that price by treatment area are giving up that ambiguity on purpose.

This is also where the question of who is holding the syringe reappears. Product selection, dilution, dose, and placement are all injector decisions, and in much of the medical spa sector those decisions are made under supervision arrangements that are looser than patients assume, a structural issue we examined in detail in our coverage of who is actually injecting you. Brand is the least important variable in that room.

The counterfeit problem was never about the brand

The short answer: the harmful cases reported in recent years involved counterfeit or improperly sourced product injected in non-medical settings, and the common thread was the setting and the supply chain rather than which trademark was on the box.

In 2024, the Centers for Disease Control and Prevention reported clusters of people across roughly a dozen states who developed botulism-like illness after cosmetic botulinum toxin injections. Some required hospitalization, and some received botulism antitoxin. The reported cases were concentrated in injections given by unlicensed individuals or in settings outside a medical practice, using product that had been counterfeited or obtained outside the legitimate distribution chain. The FDA has separately warned about counterfeit units circulating under the Botox name.

The practical lesson is unglamorous. Authentic product from any of the six approved manufacturers, reconstituted properly and injected by a qualified clinician in a medical setting, is a well-characterized treatment with a long safety record across cosmetic and therapeutic use, including its established role in conditions such as excessive sweating and in muscle-driven aesthetic work such as masseter treatment. Product bought at a discount from an unverified source and injected at somebody's kitchen table is a different transaction wearing the same word. Asking to see the vial is not rude, and a practice that treats the question as an insult has told you something.

The honest summary

Botox is a brand. The category is botulinum toxin type A, and six products in it are approved for cosmetic use in the United States. They share a mechanism, a class warning, and a general duration in the range of three to four months, with one newer formulation claiming longer and carrying evidence that is promising rather than settled.

The one piece of arithmetic worth carrying into the room is that units do not convert. They are defined per product by the manufacturer, and the FDA says directly that they are not interchangeable. Every per-unit price comparison across brands is therefore meaningless, every clinic-to-clinic transfer needs a deliberate conversion, and a weak result after a switch is more often a dosing error than a biological one.

So ask for the product name and the unit count in writing, ask for a price on the treated area rather than per unit, and ask why this product rather than another. If the answer is a purchasing relationship, that is acceptable as long as it is stated. What should not survive the conversation is the idea that you are comparing like with like when you compare two per-unit prices on two different labels. You are not, and the format exists partly because you cannot tell.